Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;26(4):e433-e438.
doi: 10.3747/co.26.4889. Epub 2019 Aug 1.

Feasibility of a modified Atkins diet in glioma patients during radiation and its effect on radiation sensitization

Affiliations

Feasibility of a modified Atkins diet in glioma patients during radiation and its effect on radiation sensitization

C Woodhouse et al. Curr Oncol. 2019 Aug.

Abstract

Background: Gliomas are the most dreaded primary brain tumour because of their dismal cure rates. Ketogenic-type diets (kds) are high-fat, low-protein, and low-carbohydrate diets; the modified Atkins diet (mad) is a less-stringent version of a kd that still generates serum ketones in patients. The purpose of the present study was to retrospectively examine the feasibility of attaining ketosis and the safety of the mad in patients undergoing radiation and chemotherapy treatment for glioma. The rate of pseudoprogression (psp) after treatment was also assessed as a marker of radiation sensitization. To our knowledge, this dataset is the largest published relating to patients with glioma undergoing kd during radiation and chemotherapy.

Methods: We retrospectively studied 29 patients with grades ii-iv astrocytoma following the mad during standard radiation and chemotherapy. Feasibility of attaining ketosis was assessed though levels of beta hydroxybutyrate in blood. Pre- and post-radiation magnetic resonance images were evaluated for psp by a neuroradiologist blinded to patient data.

Results: In the 29 patients who started the mad during radiation, ketosis was achieved in all 29 (100%). No serious adverse events occurred secondary to the mad. Of those 29 patients, 19 had glioblastoma multiforme. Of the latter 19 patients, 11 (58%) showed psp after mad and radiation and temozolomide therapy.

Conclusions: A modified Atkins diet is feasible and safe for glioma patients during radiation and chemotherapy treatment. The mad and resulting ketosis could play a role as a radiation sensitizer.

Keywords: Modified Atkins diet; glioblastoma multiforme; ketogenic diets; pseudoprogression.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.

Figures

FIGURE 1
FIGURE 1
Median serum beta-hydroxybutyrate (BHB) levels for each patient during 6 weeks of a modified Atkins diet and radiation therapy. Error bars represent the maximal BHB and the minimal BHB during the diet. KDGBM = ketogenic diet in glioblastoma multiforme.

Similar articles

Cited by

References

    1. Stupp R, Mason WP, van den Bent MJ, et al. on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the ncic Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Maurer GD, Brucker DP, Bähr O, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315. doi: 10.1186/1471-2407-11-315. - DOI - PMC - PubMed
    1. De Feyter HM, Behar KL, Rao JU, et al. A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. Neuro Oncol. 2016;18:1079–87. doi: 10.1093/neuonc/now088. - DOI - PMC - PubMed
    1. Abdelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012;7:e36197. doi: 10.1371/journal.pone.0036197. - DOI - PMC - PubMed
    1. Brandes AA, Franceschi E, Tosoni A, et al. mgmt promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–7. doi: 10.1200/JCO.2007.14.8163. - DOI - PubMed

Substances